



Universiteit
Leiden
The Netherlands

A sight for sore eyes : assessing oncogenic functions of Hdmx and reactivation of p53 as a potential cancer treatment

Lange, J. de

Citation

Lange, J. de. (2012, May 9). *A sight for sore eyes : assessing oncogenic functions of Hdmx and reactivation of p53 as a potential cancer treatment*. Retrieved from <https://hdl.handle.net/1887/18929>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/18929>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/18929> holds various files of this Leiden University dissertation.

Author: Lange, Job de

Title: A sight for sore eyes : assessing oncogenic functions of Hdmx and reactivation of p53 as a potential cancer treatment

Date: 2012-05-09

Curriculum Vitae

Job de Lange was born on the 26th of November 1982 in Zwolle. After finishing the gymnasium at the Carolus Clusius College in Zwolle in 2001, he studied Biotechnology at Wageningen University. From July 2006 until January 2007 he did a research internship at the lab of Prof. Moshe Oren at the Weizmann Institute of Science in Rehovot, Israel. This internship stimulated his interest in cancer research in general and the p53 field in particular. Therefore, after obtaining the Master degree Medical Biotechnology, in July 2007 he joined the lab of Dr. AG Jochemsen at the LUMC in Leiden for his PhD training. Since November 2011 he is working as a postdoc in the lab of Dr. Johan de Winter at the VUMC in Amsterdam.

List of publications

Lenos K*, **De Lange J***, Teunisse AF, Lodder K, Verlaan - De Vries M, Wiercinska E, Van der Burg MJ, Szuhai K and Jochemsen AG (2011). Oncogenic functions of hMDMX in *in vitro* transformation of primary human fibroblasts and embryonic retinoblasts. *Molecular Cancer* **10**, 111

De Lange J, Teunisse AF, Verlaan - De Vries M, Lodder K, Lam S, Luyten GPM, Jager MJ and Jochemsen AG (2012). High levels of Hdmx promote cell growth in a subset of uveal melanomas. *Submitted manuscript*

De Lange J, Ly LV, Lodder K, Verlaan - De Vries M, Teunisse AF, Jager MJ and Jochemsen AG (2012). Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. *Oncogene* **31**, 1105-1116

De Lange J, Verlaan - De Vries M, Teunisse AF and Jochemsen AG (2012). Chk2 mediates RITA-induced apoptosis. *Cell Death and Differentiation, in press*

Gembarska A, Luciani F, Russell E, **De Lange J**, Yip D, Goydos J, Haigh JJ, Larue L, Jochemsen AG, Ghanem G, Bernal F and Marine JC (2012). MDM4 is a key therapeutic target in Melanoma. *Submitted manuscript*

Liang CY, **De Lange J**, Chen XW, Van Oers MM, Vlak JM and Westenberg M (2012). Functional analysis of two inhibitor of apoptosis (*iap*) orthologs from *Helicoverpa armigera* nucleopolyhedrovirus. *Virus Research, in press*

Spinnler C, Hedstrom E, Li H, **De Lange J**, Nikulenkov F, Teunisse AF, Verlaan - De Vries M, Grinkevich V, Jochemsen AG and Selivanova G (2011). Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. *Cell Death and Differentiation* **18**, 1736-1745.

Phillips A, Teunisse A, Lam S, Lodder K, Darley M, Emaduddin M, Wolf A, Richter J, **De Lange J**, Verlaan - De Vries M, Lenos K, Bohnke A, Bartel F, Blaydes JP and Jochemsen AG (2010). HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity. *Journal of Biological Chemistry* **285**, 29111-29127